Skip to main content
Figure 5 | Cancer & Metabolism

Figure 5

From: Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations

Figure 5

Insignificant effects of fibroblast growth factor receptor (FGFR)4 deficiency on human epidermal growth factor receptor (Her) and FGFR expression, Her2 activation and cellularity of the mouse breasts. (A) The expression of FGFR1/2/3, Her1/2, betaKlotho (KLB), estrogen receptor (ER)α and adiponectin receptor (AdipoR)1 in the breasts and tumors from the wild-type (WT), FGFR4 knockout (KO), MMTV-TGFα transgenic (Tg) and FGFR4−/−: MMTV-TGFα bigenic (KO-Tg) mice at 6 months was analyzed by quantitative PCR (see Methods). mRNA levels were normalized to β-actin and expressed as fold change relative to that of FGFR1 in WT breasts, which was assigned an arbitrary unit of 100. (B) Comparative expression of FGFR1, FGFR4 and KLB in the white adipose tissue (WAT), liver and breast were analyzed by quantitative PCR, and expressed as changes relative to β-actin levels in the respective tissues. Indicated data are means ± SD, P <0.05 (n = 6/group). (C) Antibody array for a panel of activated kinases was done (see Methods) using tissue extracts from six mouse breasts in each of the WT, KO, Tg and KO-Tg groups. Representative micrographs of the dot blot strips for the four members of the Her family are shown. PC, positive antibody control. (D) Quantitative densitometric analyses of phosphorylated Her1 (pHer1) and Her2 from (C) shown as means ± SD, P <0.05 (n = 3). (E) Representative section of the mammary tissues from the KO mice at 6 months showing no change in the cellularity and structure of the mammary tissue.

Back to article page